Variables Total Contact Lenses Amniotic membrane p*
m (IQR) m (IQR) m (IQR)
Pain        
1st day 1 (0 -2) 1 (1–2) 0.5 (0 -1) 0.2
7th day 0.5 (0 -1) 1 (1–2) 0 (0 -0) 0.005*
30 days 0 (0–1) 1 (1–2) 0 (0 –0) 0.002*
90 days 2 (1–2.5) 1 (1–2) 2 (1 -3) 0.17
180 days 2 (1–5) 1.5 (1–2) 5 (4–6) 0.042*
Neovascularization        
1st day 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97
7th day 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97
30 days 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97
90 days 0 (0–2) 0.5 (0 -2) 0 (0 –2) 0.97
180 days 1 (0–2) 1.5 (0.5–2) 0 (0 –2) 0.58
Bullae        
1st day 1 (0–1) 0.5 (0 -1) 1 (0–1) 0.96
7th day 1 (0–1) 0.5 (0 -1) 1 (0–1) 0.86
30 days 0 (0–1) 0.5 (0 -1) 0 (0–0) 0.15
90 days 0 (0–1) 0.5 (0 -1) 0 (0–0) 0.15
180 days 0 (0–1) 0 (0–1) 0 (0–0) 0.43
Visual Sharpness        
1st day 0.0052 (0.0052–0.0096) 0.0052 (0.0052–0.014) 0.0052 (0.0033-0.0052) 0.18
7th day 0.0052 (0.0052–0.0096) 0.0052 (0.0052–0.014) 0.0052 (0.0033-0.0052) 0.18
30 days 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.0052 (0.0052-0.014) 0.84
90 days 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.84
180 days 0.0052 (0.0052–0.014) 0.0052 (0.0052–0.014) 0.0096 (0.0033- 0.014) 0.84
Table 3: Distribution of study variables in each group after the use of contact lenses (control group) or amniotic membrane grafting (AM group) for different follow-up periods. P values correspond to the statistical comparisons between the control and the AM group. m: Median; IQR: Interquartile Range.